NEWS COMMENTARY

Deinove and Hallstar France co-develop new skin microbiome-targeting cosmetic active

Published:
March 31, 2020
Coverage:
Accelerating Materials Innovation More...
Activities:
Partnership More...
Average importance

This postbiotic ingredient BIOME Oléoactif contains branched fatty acids extracted from the extremophile Deinococcus bacterial strain using Hallstar’s extraction process (originally developed by French company Oléos) based on the solvent potential of vegetable oils. The final formulation contains the postbiotic ingredient blended with jojoba liquid wax and oat oil. With a projected product launch in April 2020, Deinove joins a host of other players that develop postbiotics ingredients rendering a prebiotic effect to modulate the skin microbiome. Despite entering an increasingly crowded space, greener extraction methods and formulation effectiveness are likely to provide upcoming postbiotic products an edge in the market.

For the original news article, click here .


Further Reading

Micreos' bacteriophage-based solutions effectively combat pathogens in food safety applications

Case Study | February 04, 2020

Dutch company Micreos develops bacteriophage‑based products for food safety and human health applications. For food safety applications, the company commercializes three bacteriophage products effective against E. coli O157, Salmonella, and Listeria under the PhageGuard brand. Of these, PhageGuard ... Not part of subscription

Geltor launches animal-free elastin for skin care market

News Commentary | April 15, 2020

The company's new product Elastapure containing human elastin targets replacing animal‑derived elastin for skin care applications. Geltor focuses on both cosmetics and food applications; however, its offerings for cosmetics are slightly more advanced. It currently has three commercialized ... Not part of subscription

Pendulum Therapeutics raises $54 million for probiotic supplement targeting diabetes management

News Commentary | May 05, 2021

Led by Meritech Capital, this Series C round brings the company's funding to $111 million, allowing it to scale up manufacturing and expand sales of its first product. In January 2020, Pendulum Therapeutics (previously known as Whole Biome) launched Glucose Control, a probiotic blend consisting of ... Not part of subscription